Skip to main content
logo
Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT · Real-Time Price · USD
0.2015
-0.0358 (-15.09%)
Oct 30, 2026, 3:31 PM EDT - Market open

LABT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Net Income
-7.35-3.85-4.86-8.28
Depreciation & Amortization
0.120.120.120.12
Loss (Gain) From Sale of Investments
---0.07-0.08
Stock-Based Compensation
3.791.350.270.61
Change in Accounts Payable
0.090.21-0.330.05
Change in Other Net Operating Assets
-0.140.21-0.860.76
Operating Cash Flow
-3.49-1.94-5.72-6.82
Operating Cash Flow Growth
----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Capital Expenditures
---0-
Investment in Securities
-2-3.93-3.78
Investing Cash Flow
-2-3.92-3.78

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Short-Term Debt Issued
-1.5--
Total Debt Issued
0.21.5--
Net Debt Issued (Repaid)
-1.5--
Repurchase of Common Stock
---0.05-
Financing Cash Flow
6.81.5-0.05-

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Net Cash Flow
1.32-0.44-1.85-10.6

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-3.49-1.94-5.73-6.82
Free Cash Flow Growth
----
Free Cash Flow Per Share
-3.96-2.79-8.29-10.01
Levered Free Cash Flow
-0.91-0.53-3.5-
Unlevered Free Cash Flow
-0.83-0.46-3.5-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Cash Interest Paid
---0
Change in Working Capital
-0.050.43-1.190.81
SEC Filings: 10-K · 10-Q